
Multiple Myeloma Care: Timing, Teamwork, Treatment
Episode 23
Multiple myeloma care is evolving faster than ever, with new therapies, treatment strategies, and possibilities emerging at an unprecedented pace. In this episode, hematologist Dr. Devarakonda and Kathy Giusti, founder of the Multiple Myeloma Research Foundation, come together for a candid, practical conversation about what this rapid progress means for patients, caregivers, and providers. They explore why where you’re treated matters, how timing, sequencing, and dosing decisions shape outcomes, and what it takes to be an informed patient in today’s complex care environment. Through real-world stories and clinical insight, the conversation highlights the importance of collaboration between community and academic care teams, the growing role of the patient voice in decision-making, and the need to balance cutting-edge treatment with quality of life. Whether newly diagnosed or navigating later lines of therapy, this episode offers practical guidance for making confident, informed decisions in multiple myeloma care. Key Takeaways Multiple myeloma is increasingly treatable, with patients living longer than ever. Advances in therapy are leading to remission for many patients and significantly improving survival outcomes. Where you’re treated—and your care team—matters more than ever. The most effective care is team-based, involving academic specialists, community oncologists, and the patient along with their caregiver working together.
Publisher
HemeTalks: Conversations in Hematology Education
Link
share.transistor.fm/s/eec2437f
Published
May 21, 2026
Duration
23 min
Format
Podcast
Category
Lifestyle · Courses
Source
RSS feed
Host
American Society of Hematology
HemeTalks: Conversations in Hematology Education
@hemetalksconversationsinhema
#multiplemyelomacare #teamwork #treatment #courses #naturalsciences
